Tirzepatide in the Treatment of Cannabis Use Disorder

NCT07671248 on ClinicalTrials.gov · last registry update 2026-07-01

A small phase 3 — 15 participants, against a typical 424. Due to report 31 July 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: Tolerability of Tirzepatide-Assisted-Psychotherapy for Cannabis Use Disorder. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: McMaster University
Sponsor type: Other
Enrollment: 15
Started: 2026-08-01
Primary completion: 2028-07-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Tolerability of Tirzepatide-Assisted-Psychotherapy for Cannabis Use Disorder.

Conditions studied

Cannabis Use Disorder, Moderate · Cannabis Use Disorder, Severe

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.